



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 November 2018

Imagion Biosystems Raises \$4.3M Via Rights Issue

MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the **Company**), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it has successfully completed the placement of the shortfall shares under its recent 1-for-2 pro-rata non-renounceable rights issue offer (**Rights Issue**).

The Company has raised a total of \$4.3 million (before costs) under the Rights Issue offer and shortfall placement.

The shortfall placement, which was lead managed by Pamplona Corporate Pty Ltd (**Lead Manager**), was fully subscribed by sophisticated and professional investors.

“We are very pleased to have completed the fully subscribed shortfall placement in a timely manner, and thank all existing shareholders and new investors who participated in the rights issue offer and shortfall placement for their support,” said Bob Proulx, Executive Chairman. “With the additional funding secured we can continue to move forward with our plans for first-in-human testing of our first MagSense cancer diagnostic test next year.”

Prior to the initiation of the early feasibility first-in-human study, the Company will undertake testing of the MagSense nanoparticle formulation for safety and toxicity, resulting in a toxicology report. This is a standard but very important step, often considered a significant de-risking milestone in pharmaceutical development, as it demonstrates the biological safety of the MagSense nanoparticle formulation for human use. The toxicology report will then be used to obtain regulatory and institutional approval for the first-in-human study.

A total of 96,859,510 new shares will be issued by the Company under the shortfall placement at the Rights Issue offer price of \$0.04 per share. In addition, the Company will issue 34,420,000 Options (each exercisable at \$0.06, expiring 24 months after date of issue) to the Lead Manager (or its nominees), as part of its placement selling fees. An Appendix 3B in relation to the issue of the new securities will be lodged upon settlement of the shortfall placement, which is expected to occur this week.

-ENDS

About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense™ technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420